Company intelligence / Profile preview
Kadmus Pharmaceuticals, Inc.
Irvine, California, United Statespitchbook.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Kadmus Pharmaceuticals developed small molecule therapeutics targeting the endocannabinoid system, particularly through inhibition of FAAH. Its lead compound reached Phase 1 clinical trials for schizophrenia before the company’s core assets and technology were acquired by Organon in 2007. Other programs targeting neuralgia and glaucoma were discontinued prior to acquisition. The company’s research contributed to advancing FAAH inhibitors as a novel therapeutic class with potential applications in CNS disorders and pain management
- Therapeutic areas
- PsychiatryOphthalmologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of California Irvine (exclusive license for KDS‑4103/URB597)Organon/Akzo Nobel (acquirer of key assets and staff transfer post-acquisition)
Beyond the preview
Go deeper on Kadmus Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kadmus Pharmaceuticals, Inc..